BioStem Technologies approved for Nasdaq Capital Market listing; trading starts Aug 7

BioStem Technologies, Inc.

Nasdaq approved BSEM common stock for listing on The Nasdaq Capital Market on Aug 6, 2026.
Trading transitions from OTCQB to Nasdaq effective at market open on Aug 7, 2026; ticker remains BSEM.
No shareholder action required; CEO Jason Matuszewski cites expanded capital access and liquidity.
Company is a regenerative medicine firm focused on perinatal tissue allograft products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.